OverviewSuggest Edit

Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics, orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The Company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome, and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy and other renal diseases.

TypePublic
Founded1994
HQSeattle, US
Websiteomeros.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Dec 2019)258(+10%)
Revenue (FY, 2019)$111.8 M(+275%)
Share Price (Sept 2020)$11.7 (-5%)
Cybersecurity ratingBMore

Key People/Management at Omeros

Gregory A. Demopulos

Gregory A. Demopulos

Chairman and Chief Executive Officer
Christopher S. Bral

Christopher S. Bral

Vice President, Nonclinical Development
Ray Aspiri

Ray Aspiri

Director
Timothy M. Duffy

Timothy M. Duffy

Vice President, Business Development
Peter B. Cancelmo

Peter B. Cancelmo

Vice President, General Counsel and Secretary
Thomas F. Bumol

Thomas F. Bumol

Director
Show more

Omeros Office Locations

Omeros has an office in Seattle
Seattle, US (HQ)
Waterfront Research Center, 201 Elliott Ave W
Show all (1)

Omeros Financials and Metrics

Omeros Revenue

Omeros's revenue was reported to be $111.81 m in FY, 2019
USD

Revenue (Q2, 2020)

13.5m

Gross profit (Q2, 2020)

13.4m

Gross profit margin (Q2, 2020), %

98.9%

Net income (Q2, 2020)

(33.3m)

EBIT (Q2, 2020)

(27.7m)

Market capitalization (21-Sept-2020)

735.9m

Closing stock price (21-Sept-2020)

11.7

Cash (30-Jun-2020)

2.0m
Omeros's current market capitalization is $735.9 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.5m6.0m1.6m539.0k13.5m41.6m64.8m29.9m111.8m

Revenue growth, %

(66%)2406%208%

Cost of goods sold

1.0m1.4m1.1m512.0k865.0k

Gross profit

12.5m40.2m63.7m29.4m110.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.2m987.0k1.5m1.5m1.4m1.1m140.0k196.0k100.0k45.0k214.0k388.0k3.2m3.3m7.4m10.0m11.3m12.3m17.2m21.7m1.6m1.7m4.6m21.8m26.8m29.9m23.5m13.5m

Cost of goods sold

11.0k365.0k248.0k327.0k327.0k378.0k271.0k157.0k184.0k203.0k116.0k36.0k131.0k55.0k278.0k267.0k147.0k

Gross profit

377.0k2.8m3.0m7.1m9.7m10.9m12.0m17.0m21.5m1.4m1.5m4.6m21.6m26.7m29.6m23.3m13.4m

Gross profit Margin, %

97%89%92%96%97%97%98%99%99%87%93%99%99%100%99%99%99%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.0m1.5m1.4m354.0k1.4m2.2m3.4m5.9m3.1m

Accounts Receivable

876.0k1.9m379.0k392.0k6.5m14.6m17.1m22.8m35.2m

Prepaid Expenses

502.0k416.0k337.0k1.2m1.9m1.8m7.0m6.5m6.6m

Inventories

568.0k472.0k1.1m443.0k88.0k1.1m
USDQ2, 2011

Financial Leverage

4.1 x
Show all financial metrics

Omeros Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents (Foreign)

41 55 63

Patents Pending (Foreign)

66 72 73

Patents (US)

271 310 492

Patents Pending (US)

300 327 313
Show all operating metrics

Omeros Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Omeros Online and Social Media Presence

Embed Graph

Omeros News and Updates

Thinking about buying stock in Unum Therapeutics, Omeros Corp, Workhorse Group, Norwegian Cruise Line, or Delta Air Lines?

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UMRX, OMER, WKHS, NCLH, and DAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Latest Trends in Carasil Treatment Market 2020-2025| GlaxoSmithKline, Omeros Ipsen, Vertex Pharmaceuticals Incorporated, Raptor Pharmaceutical, H. Lundbeck A/S, Pfizer

The Carasil Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, …

Omeros stock gains on transplant drug data

Shares of Omeros Corp. rallied 7% in morning trading on positive data for narsoplimab, its experimental therapy for a complication that can occur for patients undergoing stem cell transplants. Half of the patients who underwent treatment with narsoplimab in a trial met the Food and Drug Administrat…

Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023

SEATTLE, Nov. 8, 2018 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the...
Show more

Omeros Frequently Asked Questions

  • When was Omeros founded?

    Omeros was founded in 1994.

  • Who are Omeros key executives?

    Omeros's key executives are Gregory A. Demopulos, Christopher S. Bral and Ray Aspiri.

  • How many employees does Omeros have?

    Omeros has 258 employees.

  • What is Omeros revenue?

    Latest Omeros annual revenue is $111.8 m.

  • What is Omeros revenue per employee?

    Latest Omeros revenue per employee is $433.4 k.

  • Who are Omeros competitors?

    Competitors of Omeros include BeyondSpring, Catalyst Pharmaceuticals and Akorn.

  • Where is Omeros headquarters?

    Omeros headquarters is located at Waterfront Research Center, 201 Elliott Ave W, Seattle.

  • Where are Omeros offices?

    Omeros has an office in Seattle.

  • How many offices does Omeros have?

    Omeros has 1 office.